USA – Synairgen’s inhaled COVID-19 treatment included in US trial

The Phase II/III trial ACTIV-2 study is designed to evaluate multiple investigational agents compared to placebo in adults with mild-to-moderate COVID-19, which does not require hospitalisation.

It is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), which is part of the US National Institutes of Health (NIH).

While NIAID is the regulatory sponsor and holder of the investigational new drug application to conduct the study, it is funded by Operation Warp Speed – a partnership led by the US Department of Health and Human Services through NIAID…